Hindsight is always 20/20, and it’s the same in hindsight investing. Here, I’d like to address Acer Therapeutics’ (ACER) failure with Edsivo (celiprolol) for vascular Ehlers-Danlos syndrome (vEDS). The FDA’s rejection can teach investors, myself included, valuable lessons for the future regarding uncontrolled trials backed by observational studies. I believe, in retrospect, that the complete response letter received by Acer from the Food and Drug Administration should have been expected, perhaps even on the border of obvious. What I am hoping to show is that, in the future, for companies in a similar